IL-12-Independent Pathways Mechanisms Involving ERK-1 / 2-Dependent Cancer Patients Is Controlled through Dendritic Cells from Normal Donors and and T-bet Expression in Human γ IFN -

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas

  2005cited by this paper
• Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response

  2005cited by this paper
• Interferon-γ Inhibits Hepatitis B Virus–Induced NF-κB Activation Through Nuclear Localization of NF-κB–Inducing Kinase

  2005cited by this paper
• IL-12 or IL-4 Prime Human NK Cells to Mediate Functionally Divergent Interactions with Dendritic Cells or Tumors1

  2005cited by this paper
• Interferon-gamma production by human cord blood monocyte-derived dendritic cells

  2005cited by this paper
• Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms

  2005cited by this paper
• IFN‐γ overcomes low responsiveness of myeloid dendritic cells to CpG DNA

  2005cited by this paper
• Bryostatin-1 Enhances the Maturation and Antigen-Presenting Ability of Murine and Human Dendritic Cells

  2004cited by this paper
• Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer

  2004cited by this paper
• Sustained T-bet expression confers polarized human TH2 cells with TH1-like cytokine production and migratory capacities.

  2004cited by this paper
• The Biology of the Ets1 Proto-Oncogene

  2003cited by this paper
• T-bet is required for optimal production of IFN-γ and antigen-specific T cell activation by dendritic cells

  2003influential reference
• IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-γ Production in Human NK and T Cells1

  2003cited by this paper
• A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

  2003cited by this paper
• Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.

  2003cited by this paper
• Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells

  2002cited by this paper
• IFN‐γ and pro‐inflammatory cytokine production by antigen‐presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension

  2002cited by this paper
• A Role for IFN-γ in Primary and Secondary Immunity Generated by NK Cell-Sensitive Tumor-Expressing CD80 In Vivo1

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Regulation of THI differentiation – controlling the controllers

  2002cited by this paper
• Complementary Dendritic Cell–activating Function of CD8+ and CD4+ T Cells

  2002cited by this paper
• Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.

  2001cited by this paper
• T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells

  2001cited by this paper
• Bryostatin-1 and IL-2 Synergize to Induce IFN-γ Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy1

  2001cited by this paper
• IL-12/IL-18-dependent IFN-gamma release by murine dendritic cells.

  2001cited by this paper
• Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity.

  2000cited by this paper
• IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells

  2000cited by this paper
• A novel transcription factor, T-bet, directs Th1 lineage commitment.

  2000cited by this paper
• Synergistic Effects of IL-4 and IL-18 on IL-12-Dependent IFN-γ Production by Dendritic Cells1

  2000cited by this paper
• Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

  2000cited by this paper
• The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation.

  1999cited by this paper
• Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug.

  1999cited by this paper
• Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients.

  1998cited by this paper
• Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.

  1998cited by this paper
• IL-12 induces T helper 1-directed antitumor response.

  1997cited by this paper
• The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression.

  1997cited by this paper
• Decreased antigen presentation by dendritic cells in patients with breast cancer.

  1997cited by this paper
• Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.

  1996cited by this paper
• The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.

  1996cited by this paper
• Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression

  1996cited by this paper
• Negative Transcriptional Regulation of the Interferon-γ Promoter by Glucocorticoids and Dominant Negative Mutants of c-Jun (*)

  1995cited by this paper
• Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.

  1995cited by this paper
• Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis

  1995cited by this paper
• Immune response in mice that lack the interferon-gamma receptor.

  1993cited by this paper
• In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

  1993influential reference
• Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.

  1993cited by this paper
• Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.

  1993cited by this paper
• Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo

  1993cited by this paper
• Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

  1993cited by this paper
• Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines.

  1992cited by this paper
• Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

  1992cited by this paper
• Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

  1991cited by this paper
• The Effect of Bryostatin 1 on Human Lymphocyte‐Mediated Cytotoxicity

  1991cited by this paper
• Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells.

  1988cited by this paper
• Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.

  1987cited by this paper
• Co-induction of lymphokine synthesis by the antineoplastic bryostatins.

  1987cited by this paper
• Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells.

  1986influential reference

• No citing papers are available for this paper.